Version March 2022
Version March 2022
Various statements that AC Immune makes on this Website about AC Immune’s future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, business strategy, product candidates, product pipeline, ongoing and planned clinical studies, including those of our collaboration partners, regulatory approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many forward-looking statements can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate,” “will” and “potential,” among others. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors.
In addition, any forward-looking statements represent the AC Immune’s views only as of the date such statements are made in materials on this Website, including in presentations, press releases, and should not be relied upon as representing our views as of any subsequent date. While AC Immune may elect to update these forward-looking statements at some point in the future, AC Immune specifically disclaims any obligation to do so, even if its views change. Therefore, you should not rely on these forward-looking statements as representing AC Immune’s views as of any date subsequent the date such statements are made.
For more information concerning the risks AC Immune faces, visitors to this Website should refer to the “Risk Factors” contained in AC Immune’s filings with the United States Securities and Exchange Commission.
The AC Immune name and logo, regardless of whether or not they appear in large print or with a trademark symbol, are trademarks of AC Immune. The use, reproduction, copying or redistribution of these trademarks, without the written permission of AC Immune, is prohibited. The entire content of this Website, including any image or text, is protected by copyright. In consideration for your agreement to these Terms, AC Immune grants you a personal, non-exclusive, non-transferable license to access and use this Website. You may download material from this Website only for non-commercial use, and this Website may not be copied, distributed, downloaded, modified, reused, reposted or otherwise exploited except as provided herein without the express written permission of AC Immune. The use or misuse of these trademarks, copyrights or other materials, except as permitted herein, is expressly prohibited and may be in violation of copyright law, trademark law, communications regulations and statutes, and other laws, statutes and/or regulations.
This Website may include links to websites maintained or controlled by third parties. AC Immune does not have control over such websites, does not approve or endorse the contents of such websites, and is not responsible for such content or your use of such content.
Please note that some functions on our site may be limited or unavailable if you do not accept cookies.
This Website does not, and is not intended to, provide any medical advice. The investigational products under development by AC Immune are not approved for any use outside of clinical trials. The information presented in this Website should not be interpreted or construed in any way as a replacement or substitution for medical advice provided by your healthcare provider. It is important that you discuss your treatment options and any questions that you may have with your healthcare provider.
These Terms are subject to Swiss Laws and Regulations.
This Website is owned and operated by:
AC Immune SA, located at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland
You may contact us by sending correspondence to that address or by emailing us: